BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 9, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2023

View Archived Issues
Fluorescence microscopy image of mitochondria

Mitochondrial modulator rejuvenates blood stem cells

Researchers have demonstrated that inhibiting mitophagy in ‘old’ hematopoietic stem cells (HSCs) completely restored their blood reconstitution capabilities, raising the prospect of addressing the age-related weakening of the immune system that stems from HSCs deteriorating over time. Read More

Faster than light drug discovery: Superluminal launches with $33M seed round

As its name suggests, Superluminal Medicines Inc. is aiming for speed. The startup, which closed a $33 million seed round led by RA Capital Management, is combining a biology-focused approach with a generative AI platform it says has the potential to create candidate-ready compounds in a matter of months, with its initial sights set on G protein-coupled receptor targets. Read More
3D illustration of cancer in crosshairs

SCAL-255 and SCAL-266, mitochondrial complex I inhibitors with activity against OXPHOS-dependent cancers

Researchers from Sichuan University synthesized new pyrazole amides based on the previously described NADH-ubiquinone oxidoreductase (complex I, CI) inhibitor IACS-010759. Subsequent optimization resulted in the identification of SCAL-255 and SCAL-266 as lead candidates with potent CI inhibitory activity. Read More
Bacteriophages on E. coli

Intron enters collaboration with US Army on bacteriophages for urinary tract infections

Intron Biotechnology Inc. has entered into an official contract with the U.S. Army Combat Capabilities Development Command (DEVCOM) to develop bacteriophages for combating uropathogenic Escherichia coli (UPEC) infections. DEVCOM, a subcommand of the U.S. Army Futures Command, has been working on a project to develop products that address the risk of urinary tract infections (UTIs) among soldiers exposed to austere environments, such as when deployed or undergoing training. Read More

Tyligand Bioscience patents new GTPase KRAS mutant inhibitors for cancer

Tyligand Bioscience Ltd. has disclosed GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Thrombus in bloodstream with platelets and fibrin

RBD-4059, the first siRNA-based strategy targeting FXI, is ready for human development

Current anticoagulant strategies include small-molecule inhibitors and biological entities targeting factor XI (FXI) which, although effective, still have bleeding as a major risk. Read More
Collaboration illustration

Intelligent Omics enters target discovery collaboration with Janssen in hematological cancers

Intelligent Omics Ltd. has established a target discovery collaboration with Janssen Research & Development LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to evaluate novel biological targets for the treatment of hematological cancers.

Read More

Astrazeneca divulges new IRAK4 inhibitors

Astrazeneca AB has synthesized IL-1 receptor-associated kinase 4 (IRAK4) inhibitors reported to be useful for the treatment of cancer, systemic lupus erythematosus, gout, rheumatoid arthritis, psoriasis, Sjögren’s syndrome, myositis and atopic dermatitis, among others. Read More

Nexys Therapeutics describes new AhR agonists

Nexys Therapeutics Inc. has identified aryl hydrocarbon receptor (AhR) agonists and their prodrugs reported to be useful for the treatment of inflammatory bowel disease, multiple sclerosis and Huntington’s disease. Read More
Pipet, test tubes, chemical structures

Discovery of novel MAGL inhibitor with excellent brain penetration and oral bioavailability

Monoacylglycerol lipase (MAGL), a member of the serine hydrolase family expressed in the brain and peripheral tissue, is a key enzyme in the hydrolysis of monoglycerides, converting 2-arachidonoyl glycerol (2-AG) into arachidonic acid and glycerol. MAGL inhibition has been previously shown to induce anxiolytic and analgesic phenotypes in animal models. Researchers from Janssen Pharmaceutica NV recently reported the discovery of novel noncovalent MAGL inhibitors. Read More

US researchers present new RXFP2 agonists

Researchers from Florida International University and U.S. Department of Health and Human Services have divulged fused diazepines acting as relaxin receptor 2 (RXFP2; LGR8) agonists. Read More

Arase Therapeutics discovers new PARG inhibitors for cancer

Arase Therapeutics Inc. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer. Read More
Global vaccine.png

CEPI and IVI renew collaboration on vaccines against emerging infectious diseases

The Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) have announced a renewed collaboration to accelerate the development of vaccines against emerging infectious diseases. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 9, 2025.
  • The Nasdaq Stock Exchange headquarters in New York

    Omada, Caris arrivals continue med-tech IPO hot streak

    BioWorld MedTech
    Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing